Alpha‐synuclein oligomerization and aggregation: A model will always be a model

Abstract image

The process of a‐syn aggregation is thought to be central in synucleinopathies, but has been difficult to study in the laboratory. Different models attempt to recapitulate specific aspects of the aggregation process. The BiFC assay uses engineered fusion proteins in order to enable the detection of a‐syn dimers and oligomers in living cells. As any model, it has strengths and limitations and, therefore, should only be regarded as a model for the study of basic molecular mechanisms involved in PD and other synucleinopathies. image